Literature DB >> 10365746

Prevalence of prothrombin G20210A, factor V G1691A (Leiden), and methylenetetrahydrofolate reductase (MTHFR) C677T in seven different populations determined by multiplex allele-specific PCR.

M J Hessner1, R A Luhm, S L Pearson, D J Endean, K D Friedman, R R Montgomery.   

Abstract

Individuals belonging to six racial groups (African American, Asian Indian, Caucasian, Hispanic, Korean, Native American), and a seventh group comprised of referred patients with thrombosis were genotyped for the prothrombin G20210A mutation, the factor V G1691A (Leiden) mutation, and the methylenetetrahydrofolate reductase (MTHFR) C677T mutation by multiplexed allele-specific PCR. The prothrombin 20210A and factor V 1691A allele frequencies in the thrombosis patients, 3.2% and 9.5%, were significantly higher than those in the random Caucasians, 1.3% and 1.8%, (p = 0.043 and p <0.001, respectively). The relative risk of venous thrombosis was determined to be 2.4-fold for carriers of the prothrombin 20210A allele (odds ratio = 2.54; 95% confidence interval = 0.94, 6.82) and 4.5-fold for carriers of the factor V 1691A allele (odds ratio = 5.06; 95% confidence interval = 2.25, 11.36). Among the seven populations, significant differences were observed in the MTHFR 677T allele distribution, however this mutation was not determined to be a risk factor for venous thrombosis in the patient group studied, either alone or in combination with the prothrombin 20210A and/or the factor V 1691A allele(s).

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10365746

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  19 in total

1.  A multi-site study for detection of the factor V (Leiden) mutation from genomic DNA using a homogeneous invader microtiter plate fluorescence resonance energy transfer (FRET) assay.

Authors:  M Ledford; K D Friedman; M J Hessner; C Moehlenkamp; T M Williams; R S Larson
Journal:  J Mol Diagn       Date:  2000-05       Impact factor: 5.568

2.  Identification of three genetic risk factors for venous thrombosis using a multiplex allele-specific PCR assay: comparison of conventional and new alternative methods for the preparation of DNA from clinical samples.

Authors:  Antonio Angelini; Concetta Di Febbo; Giovanna Baccante; Marcello Di Nisio; Carmine Di Ilio; Franco Cuccurullo; Ettore Porreca
Journal:  J Thromb Thrombolysis       Date:  2003-12       Impact factor: 2.300

3.  Varied prevalence of factor V G1691A (Leiden) and prothrombin G20210A single nucleotide polymorphisms among Arabs.

Authors:  Wassim Y Almawi; Sose H Keleshian; Lobna Borgi; Naglaa A Fawaz; Nisreen Abboud; Nabil Mtiraoui; Touhami Mahjoub
Journal:  J Thromb Thrombolysis       Date:  2005-12       Impact factor: 2.300

4.  Prevalence of the prothrombin G20210A polymorphism in the Lebanese population: use of a reverse hybridization strip assay approach.

Authors:  Amira S Sabbagh; Georges Ibrahim; Ziad Kanaan; Dina M R Shammaa; Rabab Abdel Khalek; Mona Ghasham; Layal Greige; Rami A R Mahfouz
Journal:  Mol Biol Rep       Date:  2007-12-08       Impact factor: 2.316

5.  Risk of venous thromboembolism associated with single and combined effects of Factor V Leiden, Prothrombin 20210A and Methylenetethraydrofolate reductase C677T: a meta-analysis involving over 11,000 cases and 21,000 controls.

Authors:  Benedetto Simone; Valerio De Stefano; Emanuele Leoncini; Jeppe Zacho; Ida Martinelli; Joseph Emmerich; Elena Rossi; Aaron R Folsom; Wassim Y Almawi; Pierre Y Scarabin; Martin den Heijer; Mary Cushman; Silvana Penco; Amparo Vaya; Pantep Angchaisuksiri; Gulfer Okumus; Donato Gemmati; Simona Cima; Nejat Akar; Kivilcim I Oguzulgen; Véronique Ducros; Christoph Lichy; Consuelo Fernandez-Miranda; Andrzej Szczeklik; José A Nieto; Jose Domingo Torres; Véronique Le Cam-Duchez; Petar Ivanov; Carlos Cantu-Brito; Veronika M Shmeleva; Mojka Stegnar; Dotun Ogunyemi; Suhair S Eid; Nicola Nicolotti; Emma De Feo; Walter Ricciardi; Stefania Boccia
Journal:  Eur J Epidemiol       Date:  2013-07-31       Impact factor: 8.082

6.  Factor V G1691A, prothrombin G20210A, and methylenetetrahydrofolate reductase [MTHFR] C677T gene polymorphism in angiographically documented coronary artery disease.

Authors:  Wassim Y Almawi; Ghada Ameen; Hala Tamim; Ramzi R Finan; Noha Irani-Hakime
Journal:  J Thromb Thrombolysis       Date:  2004-06       Impact factor: 2.300

7.  Neurocognitive Late Effects of Chemotherapy in Survivors of Acute Lymphoblastic Leukemia: Focus on Methotrexate.

Authors:  Ellen van der Plas; Brian J Nieman; Darci T Butcher; Johann K Hitzler; Rosanna Weksberg; Shinya Ito; Russell Schachar
Journal:  J Can Acad Child Adolesc Psychiatry       Date:  2015-03-04

8.  Association of MTHFR genetic polymorphisms with venous thromboembolism in Uyghur population in Xinjiang, China.

Authors:  Zhao Li; Umesh Yadav; Ailiman Mahemuti; Bao-Peng Tang; Halmurat Upur
Journal:  Int J Clin Exp Med       Date:  2015-10-15

9.  Detection of genomic polymorphisms associated with venous thrombosis using the invader biplex assay.

Authors:  Madhumita Patnaik; Jeffrey S Dlott; Robert N Fontaine; M T Subbiah; Martin J Hessner; Kelly A Joyner; Marlies R Ledford; Eduardo C Lau; Cynthia Moehlenkamp; Jean Amos; Bailing Zhang; Thomas M Williams
Journal:  J Mol Diagn       Date:  2004-05       Impact factor: 5.568

10.  Thrombotic genetic risk factors and warfarin pharmacogenetic variants in São Miguel's healthy population (Azores).

Authors:  Claudia C Branco; Tânia Pereirinha; Rita Cabral; Paula R Pacheco; Luisa Mota-Vieira
Journal:  Thromb J       Date:  2009-06-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.